Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases

Stock Information for Helix BioPharma Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Helix BioPharma Corp.

Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026
Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London
Helix BioPharma Corp. Announces Voting Results from its Annual General and Special Meeting
Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025
Helix BioPharma Corp. Announces Fiscal 2025 Year-End Results
Helix BioPharma Responds to Market Activity
Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025
Helix BioPharma Concludes Review, Will Not Proceed with Proposed Equity Draw-Down Subscription Facility with GEM

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.